NORDECS

The Natural Oscillatory Reduction of DLPFC in Early Couse Schizophrenia is our new NIMH funded (MH119543-01) study. We aim at determining whether reduced oscillatory activity of DLPFC, assessed with transcranial magnetic stimulation (TMS) with simultaneous high density (hd)-EEG, is a neurophysiological biomarker of prefrontal circuit dysfunction in SCZ, which is present in early course patients and mediate their impaired cognitive performance. Findings from this study may provide novel treatment targets to ameliorate cognitive dysfunctions in patient with SCZ early during the illness.